S
Sanjay J. Mathew
Researcher at Baylor College of Medicine
Publications - 192
Citations - 11510
Sanjay J. Mathew is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Treatment-resistant depression & Anxiety. The author has an hindex of 49, co-authored 167 publications receiving 9385 citations. Previous affiliations of Sanjay J. Mathew include Michael E. DeBakey Veterans Affairs Medical Center in Houston & Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial
James W. Murrough,Dan V. Iosifescu,Lee C. Chang,Rayan K. Al Jurdi,Charles Green,Andrew M. Perez,Syed Z Iqbal,Sarah Pillemer,Alexandra Foulkes,Asim A Shah,Dennis S. Charney,Sanjay J. Mathew +11 more
TL;DR: Ketamine demonstrated rapid antidepressant effects in an optimized study design, further supporting NMDA receptor modulation as a novel mechanism for accelerated improvement in severe and chronic forms of depression.
Journal ArticleDOI
Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression
James W. Murrough,Andrew M. Perez,Sarah Pillemer,Jessica Stern,Michael K. Parides,Marije aan het Rot,Katherine A. Collins,Sanjay J. Mathew,Sanjay J. Mathew,Dennis S. Charney,Dan V. Iosifescu +10 more
TL;DR: Ketamine was associated with a rapid antidepressant effect in TRD that was predictive of a sustained effect and future controlled studies will be required to identify strategies to maintain an antidepressant response among patients who benefit from a course of ketamine.
Journal ArticleDOI
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
Marije aan het Rot,Katherine A. Collins,James W. Murrough,Andrew M. Perez,David Reich,Dennis S. Charney,Sanjay J. Mathew +6 more
TL;DR: These pilot findings suggest feasibility of repeated-dose IV ketamine for the acute treatment of TRD and change from baseline in the Montgomery-Asberg Depression Rating Scale score.
Journal ArticleDOI
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
TL;DR: Preliminary findings support the premise that ketamine has rapid beneficial effects on suicidal cognition and warrants further study.
Journal ArticleDOI
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis
Samuel T. Wilkinson,Elizabeth D. Ballard,Michael H. Bloch,Sanjay J. Mathew,James W. Murrough,Adriana Feder,P. Sos,Gang Wang,Carlos A. Zarate,Gerard Sanacora +9 more
TL;DR: Ketamine rapidly reduced suicidal thoughts, within 1 day and for up to 1 week in depressed patients with suicidal ideation, although subsequent trials in transdiagnostic samples are required to confirm that ketamine exerts a specific effect on suicidal Ideation.